AccuStem Sciences to Offer its MSC Blood Test to Lung Cancer Screening Programs in the United States - Accustem Sciences (OTC:ACUT)

Contributing sentiments towards policy:

52% : While the uptake of these programs has been slow, 2024 saw a record number of LDCT screens for high-risk patients, and clinicians expect this trend to continue as public education improves.
51% : Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, our ability to raise capital to fund continuing operations; our ability to protect our intellectual property rights; the impact of any infringement actions or other litigation brought against us; competition from other providers and products; our ability to develop and commercialize products and services; changes in government regulation; our ability to complete capital raising transactions; and other factors relating to our industry, our operations and results of operations.

*Our bias meter rating uses data science including sentiment analysis, machine learning and our proprietary algorithm for determining biases in news articles. Bias scores are on a scale of -100% to 100% with higher negative scores being more liberal and higher positive scores being more conservative, and 0% being neutral. The rating is an independent analysis and is not affiliated nor sponsored by the news source or any other organization.